US5516653A
(en)
*
|
1993-12-28 |
1996-05-14 |
Synaptic Pharmaceutical Corporation |
DNA encoding a human neuropeptide Y/peptide YY/pancreatic polypeptide receptor (Y4) and uses thereof
|
US5545549A
(en)
|
1994-02-03 |
1996-08-13 |
Synaptic Pharmaceutical Corporation |
DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof
|
US5989920A
(en)
|
1994-12-02 |
1999-11-23 |
Synaptic Pharmaceutical Corporation |
Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
|
US5602024A
(en)
|
1994-12-02 |
1997-02-11 |
Synaptic Pharmaceutical Corporation |
DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
|
US5912227A
(en)
*
|
1995-01-27 |
1999-06-15 |
North Carolina State University |
Method of enhancing nutrient uptake
|
US6861053B1
(en)
*
|
1999-08-11 |
2005-03-01 |
Cedars-Sinai Medical Center |
Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
|
US7048906B2
(en)
|
1995-05-17 |
2006-05-23 |
Cedars-Sinai Medical Center |
Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
|
US6558708B1
(en)
*
|
1995-05-17 |
2003-05-06 |
Cedars-Sinai Medical Center |
Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
|
FR2735983B1
(fr)
|
1995-06-29 |
1997-12-05 |
Centre Nat Rech Scient |
Peptide permettant de modifier l'activite du systeme immunitaire humain ou animal
|
AU772915B2
(en)
*
|
1996-06-05 |
2004-05-13 |
Prince Of Wales Medical Research Institute Limited |
Neuropeptide Y agonists
|
US6696409B1
(en)
|
1996-06-05 |
2004-02-24 |
Prince Of Wales Medical Research Institute Limited (Powmr Ltd.) |
Neuropeptide Y agonists
|
AUPO029096A0
(en)
*
|
1996-06-05 |
1996-07-04 |
Crc For Biopharmaceutical Research Pty Ltd |
Npy y2 agonists
|
US6713265B1
(en)
|
1997-06-04 |
2004-03-30 |
Synaptic Pharmaceutical Corporation |
Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
|
US5916869A
(en)
*
|
1997-06-13 |
1999-06-29 |
North Carolina State University |
Method of treating birds in ovo
|
JP4394279B2
(ja)
*
|
1998-03-09 |
2010-01-06 |
ジーランド ファーマ アクティーゼルスカブ |
酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体
|
US6046167A
(en)
*
|
1998-03-25 |
2000-04-04 |
University Of Cincinnati |
Peptide YY analogs
|
WO2000047219A2
(en)
|
1999-02-10 |
2000-08-17 |
Ontogeny, Inc. |
Methods and reagents for treating glucose metabolic disorders
|
US7745216B2
(en)
*
|
1999-02-10 |
2010-06-29 |
Curis, Inc. |
Methods and reagents for treating glucose metabolic disorders
|
US7601691B2
(en)
|
1999-05-17 |
2009-10-13 |
Conjuchem Biotechnologies Inc. |
Anti-obesity agents
|
US6734166B1
(en)
*
|
2000-02-08 |
2004-05-11 |
North Carolina State University |
Method of reducing aluminum levels in the central nervous system
|
AU2007200008B2
(en)
*
|
2000-04-10 |
2008-09-11 |
Cedars-Sinai Medical Center |
Methods for Manipulating Upper Gastrointestinal Transit, Blood Flow, and Satiety, and for Treating Visceral Hyperalgesia
|
EP1349563B1
(en)
|
2000-12-14 |
2009-12-02 |
Amylin Pharmaceuticals, Inc. |
Peptide pyy[3-36] for treatment of metabolic disorders
|
GB0121709D0
(en)
*
|
2001-09-07 |
2001-10-31 |
Imp College Innovations Ltd |
Food inhibition agent
|
EP2050460A1
(en)
|
2001-09-24 |
2009-04-22 |
Imperial Innovations Limited |
PYY and agonists thereof for modification of feeding behaviour
|
US8058233B2
(en)
*
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
AU2003201998C1
(en)
|
2002-01-10 |
2012-10-25 |
Imperial Innovations Limited |
Modification of feeding behavior
|
AU2003243545A1
(en)
*
|
2002-06-14 |
2003-12-31 |
Amylin Pharmaceuticals, Inc. |
Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof
|
EA008829B1
(ru)
*
|
2002-12-17 |
2007-08-31 |
Нэстек Фармасьютикал Кампани Инк. |
Композиции и способы для усовершенствованной доставки пептидов, связывающихся с y-рецепторами, которую осуществляют через слизистые оболочки, и способы лечения и предотвращения ожирения
|
US7186692B2
(en)
*
|
2002-12-17 |
2007-03-06 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
|
US7166575B2
(en)
|
2002-12-17 |
2007-01-23 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
|
US7229966B2
(en)
*
|
2002-12-17 |
2007-06-12 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
|
GB0300571D0
(en)
*
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
WO2004066966A2
(en)
|
2003-01-17 |
2004-08-12 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. |
Peptide yy analogs
|
US7780973B2
(en)
*
|
2003-12-15 |
2010-08-24 |
Ethicon Endo-Surgery, Inc. |
Method and device for minimally invasive implantation of biomaterial
|
EP2422806A3
(en)
*
|
2004-02-11 |
2012-06-13 |
Amylin Pharmaceuticals Inc. |
Hybrid polypeptides with selectable properties
|
WO2005077094A2
(en)
|
2004-02-11 |
2005-08-25 |
Amylin Pharmaceuticals, Inc. |
Pancreatic polypeptide family motifs and polypeptides comprising the same
|
US8076288B2
(en)
*
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
EP1807099A2
(en)
*
|
2004-03-17 |
2007-07-18 |
7TM Pharma A/S |
Y2 selective receptor agonists for therapeutic interventions
|
EP1786458A2
(en)
*
|
2004-03-17 |
2007-05-23 |
7TM Pharma A/S |
Y2/y4 selective receptor agonists for therapeutic interventions
|
CN1953763A
(zh)
*
|
2004-03-17 |
2007-04-25 |
7Tm制药联合股份有限公司 |
用于治疗性干预的y4选择性受体激动剂
|
KR101272402B1
(ko)
|
2004-12-13 |
2013-06-10 |
아스트라제네카 파마수티컬스 엘피 |
췌장 폴리펩티드 족 모티프, 폴리펩티드 및 이를 포함하는방법
|
US7410949B2
(en)
|
2005-01-18 |
2008-08-12 |
Hoffmann-La Roche Inc. |
Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
|
US8283312B2
(en)
*
|
2005-02-04 |
2012-10-09 |
The Research Foundation Of State University Of New York |
Compositions and methods for modulating body weight and treating obesity-related disorders
|
PA8660701A1
(es)
*
|
2005-02-04 |
2006-09-22 |
Pfizer Prod Inc |
Agonistas de pyy y sus usos
|
WO2007022123A2
(en)
*
|
2005-08-11 |
2007-02-22 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
GB0504857D0
(en)
*
|
2005-03-09 |
2005-04-13 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
GB0511986D0
(en)
*
|
2005-06-13 |
2005-07-20 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
EP2330125A3
(en)
*
|
2005-08-11 |
2012-12-12 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
CA2623088A1
(en)
*
|
2005-09-21 |
2007-04-12 |
7Tm Pharma A/S |
Y4 selective receptor agonists for therapeutic interventions
|
WO2007038943A1
(en)
*
|
2005-09-21 |
2007-04-12 |
7Tm Pharma A/S |
Y2 selective receptor agonists for therapeutic interventions
|
CN101277960A
(zh)
|
2005-09-29 |
2008-10-01 |
默克公司 |
作为黑皮质素-4受体调节剂的酰化螺哌啶衍生物
|
US20070232537A1
(en)
*
|
2005-12-19 |
2007-10-04 |
Nastech Pharmaceutical Company Inc. |
Intranasal pyy formulations with improved transmucosal pharmacokinetics
|
US20070197445A1
(en)
|
2006-01-18 |
2007-08-23 |
University Of Cincinnati |
Compounds for control of appetite
|
CA2664113C
(en)
|
2006-09-22 |
2013-05-28 |
Merck & Co., Inc. |
Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
US20090099074A1
(en)
*
|
2007-01-10 |
2009-04-16 |
Conjuchem Biotechnologies Inc. |
Modulating food intake
|
US8106086B2
(en)
|
2007-04-02 |
2012-01-31 |
Msd K.K. |
Indoledione derivative
|
GB0708226D0
(en)
*
|
2007-04-27 |
2007-06-06 |
7Tm Pharma As |
Y-receptor agonists
|
US8829159B2
(en)
*
|
2008-04-14 |
2014-09-09 |
The General Hospital Corporation |
Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma
|
US8299023B2
(en)
|
2008-09-17 |
2012-10-30 |
Hoffmann-La Roche Inc. |
Neuropeptide-2 receptor (Y-2R) agonists
|
WO2010091122A1
(en)
|
2009-02-03 |
2010-08-12 |
Amunix, Inc. |
Extended recombinant polypeptides and compositions comprising same
|
JP5767582B2
(ja)
|
2009-07-02 |
2015-08-19 |
武田薬品工業株式会社 |
ペプチド及びその用途
|
TW201138808A
(en)
|
2010-05-03 |
2011-11-16 |
Bristol Myers Squibb Co |
Serum albumin binding molecules
|
WO2012080471A1
(en)
|
2010-12-16 |
2012-06-21 |
Novo Nordisk A/S |
Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
|
CN104302408B
(zh)
|
2012-02-27 |
2016-12-14 |
阿穆尼克斯运营公司 |
Xten缀合组合物和制造其的方法
|
US10933120B2
(en)
|
2012-03-22 |
2021-03-02 |
Novo Nordisk A/S |
Compositions of GLP-1 peptides and preparation thereof
|
US10246497B2
(en)
|
2013-11-15 |
2019-04-02 |
Novo Nordisk A/S |
Selective PYY compounds and uses thereof
|
CN105764919B
(zh)
|
2013-11-15 |
2021-04-27 |
诺和诺德股份有限公司 |
在位置35具有β-高精氨酸置换的hPYY(1-36)
|
JP6731958B2
(ja)
*
|
2015-06-12 |
2020-07-29 |
ノヴォ ノルディスク アー/エス |
選択的pyy化合物及びその使用
|
EP3503729A4
(en)
|
2016-08-28 |
2020-03-25 |
The State of Isreal, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) |
METHOD FOR CONTROLLING MUSHROOM INFECTIONS IN PLANTS
|
EP3746111B1
(en)
|
2018-02-02 |
2023-07-19 |
Novo Nordisk A/S |
Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
|
IL292863A
(en)
|
2019-11-13 |
2022-07-01 |
Amunix Pharmaceuticals Inc |
Barcoded xanthan polypeptides and their compositions, and methods for their preparation and use
|